Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study-Reference-Cited by-同舟云学术

Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study

Published:2021-10-19 Issue:11 Volume:41 Page:1173-1182
ISSN:2523-3548
Container-title:Cancer Communications
language:en
Short-container-title:Cancer Communications

Author:

Peng Zhi¹,Liu Tianshu²,Wei Jia³,Wang Airong⁴,He Yifu⁵,Yang Liuzhong⁶,Zhang Xizhi⁷,Fan Nanfeng⁸,Luo Suxia⁹,Li Zhen¹⁰,Gu Kangsheng¹¹,Lu Jianwei¹²,Xu Jianming¹³,Fan Qingxia¹⁴,Xu Ruihua¹⁵,Zhang Liangming¹⁶,Li Enxiao¹⁷,Sun Yuping¹⁸,Yu Guohua¹⁹,Bai Chunmei²⁰,Liu Yong²¹,Zeng Jiangzheng²²,Ying Jieer²³,Liang Xinjun²⁴,Xu Nong²⁵,Gao Chao²⁶,Shu Yongqian²⁷^ORCID,Ma Dong²⁸,Dai Guanghai²⁹,Li Shengmian³⁰,Deng Ting³¹,Cui Yuehong²,Fang Jianmin³²,Ba Yi³¹^ORCID,Shen Lin¹

Affiliation:

1. Department of Gastrointestinal Oncology Key Laboratory of Cancinogenesis and Translational Research (Ministry of Education) Peking University Cancer Hospital & Institute Beijing 100142 P. R. China

2. Department of Gastrointestinal Oncology Affiliated Zhongshan Hospital of Fudan University Shanghai 200032 P. R. China

3. Department of Oncology Nanjing Drum Tower Hospital the Affiliated Hospital of Nanjing University Medical School Nanjing Jiangsu 210008 P. R. China

4. Department of Oncology Weihai Municipal Hospital Weihai Shandong 264299 P. R. China

5. Department of Oncology Anhui Provincial Cancer Hospital Hefei Anhui 230031 P. R. China

6. Department of Oncology The First Affiliated Hospital of Xinxiang Medical College Xinxiang Henan 453100 P. R. China

7. Department of Oncology Subei People's Hospital Yangzhou Jiangsu 225009 P. R. China

8. Department of Abdominal Oncology Fujian Provincial Cancer Hospital Fuzhou Fujian 350014 P. R. China

9. Department of Gastrointestinal Oncology Henan Cancer Hospital Zhengzhou Henan 450003 P. R. China

10. Department of Oncology Linyi Cancer Hospital Linyi Shandong 276002 P. R. China

11. Department of Oncology The First Affiliated Hospital of Anhui Medical University Hefei Anhui 230022 P. R. China

12. Department of Oncology Jiangsu Cancer Hospital Nanjing Jiangsu 210009 P. R. China

13. Department of Oncology The Fifth Medical Center of PLA General Hospital Beijing 100039 P. R. China

14. Department of Oncology The First Affiliated Hospital of Zhengzhou Zhengzhou Henan 450099 P. R. China

15. Department of Oncology Sun Yat‐sen University Cancer Center Guangzhou Guangdong 510060 P. R. China

16. Department of Oncology Yantai Yuhuangding Hospital Yantai Shandong 264099 P. R. China

17. Department of Oncology The First Affiliated Hospital of Xi'an Jiaotong University Xi'an Shanxi 710061 P. R. China

18. Department of Oncology Jinan Central Hospital Jinan Shandong 250013 P. R. China

19. Department of Oncology Weifang People's Hospital Weifang Shandong 261041 P. R. China

20. Department of Oncology Peking Union Medical College Hospital Beijing 100005 P. R. China

21. Department of Oncology Xuzhou Central Hospital Xuzhou Jiangsu 221009 P. R. China

22. Department of Oncology The First Affiliated Hospital of Hainan Hospital Haikou Hainan 570102 P. R. China

23. Department of Abdominal Oncology Zhejiang Cancer Hospital Hangzhou Zhejiang 310005 P. R. China

24. Department of Oncology Hubei Cancer Hospital Wuhan Hubei 430079 P. R. China

25. Department of Oncology The First Affiliated Hospital of Zhejiang University Hangzhou Zhejiang 310003 P. R. China

26. Department of Oncology The Affiliated Hospital of Xuzhou Medical University Xuzhou Jiangsu 221004 P. R. China

27. Department of Oncology Jiangsu Province Hospital Nanjing Jiangsu 210029 P. R. China

28. Department of Oncology Guangdong Provincial People's Hospital Guangzhou Guangdong 510080 P. R. China

29. Department of Oncology Chinese PLA General Hospital Beijing 100036 P. R. China

30. Department of Gastrointestinal Oncology The Fourth Hospital of Hebei Medical University Shijiazhuang Hebei 050011 P. R. China

31. Department of Gastrointestinal Oncology Tianjin Medical University Cancer Institute and Hospital Tianjin 300181 P. R. China

32. RemeGen, Ltd. Beijing 100020 P. R. China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cac2.12214

Reference28 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung H;CA Cancer J Clin,2020

2. Report of cancer epidemiology in China, 2015;Zheng RS;Zhonghua Zhong Liu Za Zhi,2019

3. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

4. NCCN Clinical Practice Guidelines in Oncology: Gastric cancer(version 2.2020).https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf

5. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular mechanisms of HER2-targeted therapy and strategies to overcome the drug resistance in colorectal cancer;Biomedicine & Pharmacotherapy;2024-10

2. Unveiling promising targets in gastric cancer therapy: A comprehensive review;Molecular Therapy: Oncology;2024-09

3. Real-world efficacy and toxicity data of paclitaxel and ramucirumab compared with other treatment regimens in patients with advanced gastric cancer;ESMO Gastrointestinal Oncology;2024-09

4. Management of Neurotoxic Reactions Induced by Antibody-Drug Conjugates;Asia-Pacific Journal of Oncology Nursing;2024-09

5. Post-marketing drug safety surveillance of enfortumab vedotin: an observational pharmacovigilance study based on a real-world database;Frontiers in Immunology;2024-08-20